Basic Information
| RNALocate ID: | RLID:11001818 |
| RNA Symbol: | hsa-miR-145-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-145-5p |
| RNA ID: | miRBase:MIMAT0000437 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23663360 |
| Tissue/Cell Line: | Plasma |
| Method: | Next-generation RNA sequencing |
| Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001789 | Cytoplasm | Human colon cancer cell line (HCT-116) | 28964256 |
| RLID:01001790 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001791 | Nucleus | Myoepithelial cells | 29073169 |
| RLID:11001812 | Exosome | EBV- and KSHV-negative Burkitt lymphoma cell line (Bjab)|EBV-infected lymphoblastoid cell line (LCL)|KSHV-infected lymphoma cell lines (BCBL-1|TY-1) | 27611973 |
| RLID:11001813 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11001814 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11001815 | Exosome | Renal cancer cells | 21670082 |
| RLID:11001816 | Exosome | Breast milk | 22211110 |
| RLID:11001817 | Exosome | Brain tissue | 23382797 |
| RLID:11001819 | Exosome | Serum | 25135963 |
| RLID:11001820 | Exosome | Cerebrospinal fluid | 25420022 |
| RLID:11001821 | Microvesicle | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11005569 | Exosome | Peripheral blood | 32785072 |
| RLID-D:11000365 | Microvesicle | Fibroblasts|Mesenchymal stem cells|Urine | |
| RLID-D:11001178 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-145-5p | Diffuse large b cell lymphoma | MNDR-E-MI-14880 |
| MNDR | hsa-miR-145-5p | Colorectal adenoma | MNDR-E-MI-14881 |
| MNDR | hsa-miR-145-5p | Oral squamous cell carcinoma | MNDR-E-MI-14882 |
| MNDR | hsa-miR-145-5p | Large cell neuroendocrine cancer | MNDR-E-MI-14883 |
| MNDR | hsa-miR-145-5p | Medulloblastoma | MNDR-E-MI-14884 |
| MNDR | hsa-miR-145-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-14885 |
| MNDR | hsa-miR-145-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-14886 |
| MNDR | hsa-miR-145-5p | Lymphoma | MNDR-E-MI-14887 |
| MNDR | hsa-miR-145-5p | Non-hodgkin lymphoma | MNDR-E-MI-14888 |
| MNDR | hsa-miR-145-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-14889 |
| MNDR | hsa-miR-145-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-14890 |
| MNDR | hsa-miR-145-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-14891 |
| MNDR | hsa-miR-145-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-14892 |
| MNDR | hsa-miR-145-5p | Her2-receptor positive breast cancer | MNDR-E-MI-14893 |
| MNDR | hsa-miR-145-5p | Breast cancer luminal | MNDR-E-MI-14894 |
| MNDR | hsa-miR-145-5p | Neurofibromatosis 1 | MNDR-E-MI-14895 |
| MNDR | hsa-miR-145-5p | Dermatomyositis | MNDR-E-MI-14896 |
| MNDR | hsa-miR-145-5p | Agressive prostate cancer | MNDR-E-MI-14897 |
| MNDR | hsa-miR-145-5p | Bone metastasis of prostate cancer | MNDR-E-MI-14898 |
| MNDR | hsa-miR-145-5p | B-cell malignancy | MNDR-E-MI-14899 |
| MNDR | hsa-miR-145-5p | Gastric cancer | MNDR-E-MI-14900 |
| MNDR | hsa-miR-145-5p | Alzheimer disease | MNDR-E-MI-14901 |
| MNDR | hsa-miR-145-5p | Hypertension | MNDR-E-MI-14902 |
| MNDR | hsa-miR-145-5p | Intracranial aneurysm | MNDR-E-MI-14903 |
| MNDR | hsa-miR-145-5p | Bladder cancer | MNDR-E-MI-14904 |
| MNDR | hsa-miR-145-5p | Esophageal carcinoma | MNDR-E-MI-14905 |
| MNDR | hsa-miR-145-5p | Dysautonomia familial | MNDR-E-MI-14906 |
| MNDR | hsa-miR-145-5p | Myotonic dystrophy | MNDR-E-MI-14907 |
| MNDR | hsa-miR-145-5p | Head and neck cancer | MNDR-E-MI-14908 |
| MNDR | hsa-miR-145-5p | Leukemia | MNDR-E-MI-14909 |
| MNDR | hsa-miR-145-5p | Huntington disease | MNDR-E-MI-14910 |
| MNDR | hsa-miR-145-5p | Chorea | MNDR-E-MI-14911 |
| MNDR | hsa-miR-145-5p | Cardiovascular disease | MNDR-E-MI-14912 |
| MNDR | hsa-miR-145-5p | Carotid stenosis | MNDR-E-MI-14913 |
| MNDR | hsa-miR-145-5p | Moyamoya disease | MNDR-E-MI-14914 |
| MNDR | hsa-miR-145-5p | Lung cancer | MNDR-E-MI-14915 |
| MNDR | hsa-miR-145-5p | Endometrial cancer | MNDR-E-MI-14916 |
| MNDR | hsa-miR-145-5p | Down syndrome | MNDR-E-MI-14917 |
| MNDR | hsa-miR-145-5p | Parkinson disease | MNDR-E-MI-14918 |
| MNDR | hsa-miR-145-5p | Colonic adenomas | MNDR-E-MI-14919 |
| MNDR | hsa-miR-145-5p | Basal-like breast cancer | MNDR-E-MI-14920 |
| MNDR | hsa-miR-145-5p | Cancer | MNDR-E-MI-14921 |
| MNDR | hsa-miR-145-5p | Congenital heart disease | MNDR-E-MI-14922 |
| MNDR | hsa-miR-145-5p | Squamous cell carcinoma | MNDR-E-MI-14923 |
| MNDR | hsa-miR-145-5p | Vascular diseases | MNDR-E-MI-14924 |
| MNDR | hsa-miR-145-5p | Thyroid cancer | MNDR-E-MI-14925 |
| MNDR | hsa-miR-145-5p | Pituitary neoplasms | MNDR-E-MI-14926 |
| MNDR | hsa-miR-145-5p | Pancreatic cancer | MNDR-E-MI-14927 |
| MNDR | hsa-miR-145-5p | Melanoma | MNDR-E-MI-14928 |
| MNDR | hsa-miR-145-5p | Lesch-nyhan syndrome | MNDR-E-MI-14929 |
| MNDR | hsa-miR-145-5p | Rectum adenocarcinoma | MNDR-E-MI-14930 |
| MNDR | hsa-miR-145-5p | Nephroblastoma | MNDR-E-MI-14931 |
| MNDR | hsa-miR-145-5p | Colon cancer | MNDR-E-MI-14932 |
| MNDR | hsa-miR-145-5p | Colon adenocarcinoma | MNDR-E-MI-14933 |
| MNDR | hsa-miR-145-5p | Multiple sclerosis | MNDR-E-MI-14934 |
| MNDR | hsa-miR-145-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-14935 |
| MNDR | hsa-miR-145-5p | Acromegaly | MNDR-E-MI-14936 |
| MNDR | hsa-miR-145-5p | Prostate adenocarcinoma | MNDR-E-MI-14937 |
| MNDR | hsa-miR-145-5p | Kidney cancer | MNDR-E-MI-14938 |
| MNDR | hsa-miR-145-5p | Endometrial carcinoma | MNDR-E-MI-14939 |
| MNDR | hsa-miR-145-5p | Carcinoma ductal breast | MNDR-E-MI-14940 |
| MNDR | hsa-miR-145-5p | Glioblastoma | MNDR-E-MI-14941 |
| MNDR | hsa-miR-145-5p | Glioma | MNDR-E-MI-14942 |
| MNDR | hsa-miR-145-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-14943 |
| MNDR | hsa-miR-145-5p | Central nervous system lymphoma | MNDR-E-MI-14944 |
| MNDR | hsa-miR-145-5p | Chordoma | MNDR-E-MI-14945 |
| MNDR | hsa-miR-145-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-14946 |
| MNDR | hsa-miR-145-5p | Osteosarcoma | MNDR-E-MI-14947 |
| MNDR | hsa-miR-145-5p | Ewing sarcoma | MNDR-E-MI-14948 |
| MNDR | hsa-miR-145-5p | Liposarcoma | MNDR-E-MI-14949 |
| MNDR | hsa-miR-145-5p | Coronary artery disease | MNDR-E-MI-14950 |
| MNDR | hsa-miR-145-5p | Carotid artery thrombosis | MNDR-E-MI-14951 |
| MNDR | hsa-miR-145-5p | Inclusion body myositis | MNDR-E-MI-14952 |
| MNDR | hsa-miR-145-5p | Breast carcinoma | MNDR-E-MI-14953 |
| MNDR | hsa-miR-145-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-14954 |
| MNDR | hsa-miR-145-5p | Meningioma | MNDR-E-MI-14955 |
| MNDR | hsa-miR-145-5p | Liver cancer | MNDR-E-MI-14956 |
| MNDR | hsa-miR-145-5p | Uterine cancer | MNDR-E-MI-14957 |
| MNDR | hsa-miR-145-5p | Gastric adenocarcinoma | MNDR-E-MI-14958 |
| MNDR | hsa-miR-145-5p | Cervical squamous cell carcinoma | MNDR-E-MI-14959 |
| MNDR | hsa-miR-145-5p | Pituitary adenoma | MNDR-E-MI-14960 |
| MNDR | hsa-miR-145-5p | Lung squamous cell carcinoma | MNDR-E-MI-14961 |
| MNDR | hsa-miR-145-5p | Carcinoma lung non-small-cell | MNDR-E-MI-14962 |
| MNDR | hsa-miR-145-5p | Lung adenocarcinoma | MNDR-E-MI-14963 |
| MNDR | hsa-miR-145-5p | Adrenocortical carcinoma | MNDR-E-MI-14964 |
| MNDR | hsa-miR-145-5p | Thyroid carcinoma | MNDR-E-MI-14965 |
| MNDR | hsa-miR-145-5p | Ovarian carcinoma | MNDR-E-MI-14966 |
| MNDR | hsa-miR-145-5p | Bladder urothelial carcinoma | MNDR-E-MI-14967 |
| MNDR | hsa-miR-145-5p | Pancreatic adenocarcinoma | MNDR-E-MI-14968 |
| MNDR | hsa-miR-145-5p | Liver disease | MNDR-E-MI-14969 |
| MNDR | hsa-miR-145-5p | Skin cancer | MNDR-E-MI-14970 |
| MNDR | hsa-miR-145-5p | Intrastent restenosis | MNDR-E-MI-14971 |
| MNDR | hsa-miR-145-5p | Cervical cancer | MNDR-E-MI-14972 |
| MNDR | hsa-miR-145-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-14973 |
| MNDR | hsa-miR-145-5p | Carcinoma renal cell | MNDR-E-MI-14974 |
| MNDR | hsa-miR-145-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-14975 |
| MNDR | hsa-miR-145-5p | Clear cell renal cell carcinoma | MNDR-E-MI-14976 |
| MNDR | hsa-miR-145-5p | Large cell carcinoma | MNDR-E-MI-14977 |
| MNDR | hsa-miR-145-5p | Biliary tract cancer | MNDR-E-MI-14978 |
| MNDR | hsa-miR-145-5p | Adenocarcinoma of esophagus | MNDR-E-MI-14979 |
| MNDR | hsa-miR-145-5p | Cholangiocarcinoma | MNDR-E-MI-14980 |
| MNDR | hsa-miR-145-5p | Esophageal cancer | MNDR-E-MI-14981 |
| MNDR | hsa-miR-145-5p | Oncocytoma | MNDR-E-MI-14982 |
| MNDR | hsa-miR-145-5p | Lung small cell carcinoma | MNDR-E-MI-14983 |
| MNDR | hsa-miR-145-5p | Encephalopathy bovine spongiform | MNDR-E-MI-14984 |
| MNDR | hsa-miR-145-5p | Synovial sarcoma | MNDR-E-MI-14985 |
| MNDR | hsa-miR-145-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-14986 |
| MNDR | hsa-miR-145-5p | Testicular germ cell cancer | MNDR-E-MI-14987 |
| MNDR | hsa-miR-145-5p | Heart failure | MNDR-E-MI-14988 |
| MNDR | hsa-miR-145-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-14989 |
| MNDR | hsa-miR-145-5p | Fibromyalgia | MNDR-E-MI-14990 |
| MNDR | hsa-miR-145-5p | Encephalomyelitis | MNDR-E-MI-14991 |
| MNDR | hsa-miR-145-5p | Pulmonary arterial hypertension | MNDR-E-MI-14992 |
| MNDR | hsa-miR-145-5p | Adenoma | MNDR-E-MI-14993 |
| MNDR | hsa-miR-145-5p | Breast invasive carcinoma | MNDR-E-MI-14994 |
| MNDR | hsa-miR-145-5p | Hepatocellular carcinoma | MNDR-E-MI-14995 |
| MNDR | hsa-miR-145-5p | Embryonal cancer | MNDR-E-MI-14996 |
| MNDR | hsa-miR-145-5p | B-cell non-hodgkin lymphoma | MNDR-E-MI-14997 |
| MNDR | hsa-miR-145-5p | Rheumatoid arthritis | MNDR-E-MI-14998 |
| MNDR | hsa-miR-145-5p | Chronic kidney disease | MNDR-E-MI-14999 |
| MNDR | hsa-miR-145-5p | Barrett's adenocarcinoma | MNDR-E-MI-15000 |
| MNDR | hsa-miR-145-5p | Hodgkin disease | MNDR-E-MI-15001 |
| MNDR | hsa-miR-145-5p | Burkitt lymphoma | MNDR-E-MI-15002 |
| MNDR | hsa-miR-145-5p | Dementia vascular | MNDR-E-MI-15003 |
| MNDR | hsa-miR-145-5p | Acute myelocytic leukemia | MNDR-E-MI-15004 |
| MNDR | hsa-miR-145-5p | Colorectal cancer | MNDR-E-MI-15005 |
| MNDR | hsa-miR-145-5p | Acute myocardial infarction | MNDR-E-MI-15006 |
| MNDR | hsa-miR-145-5p | Multiple myeloma | MNDR-E-MI-15007 |
| MNDR | hsa-miR-145-5p | Ovarian epithelial cancer | MNDR-E-MI-15008 |
| MNDR | hsa-miR-145-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-15009 |
| MNDR | hsa-miR-145-5p | Uterine cervical neoplasms | MNDR-E-MI-15010 |
| MNDR | hsa-miR-145-5p | Nasopharyngeal cancer | MNDR-E-MI-15011 |
| MNDR | hsa-miR-145-5p | Prostatic neoplasms | MNDR-E-MI-15012 |
| MNDR | hsa-miR-145-5p | Sleep deprivation | MNDR-E-MI-15013 |
| MNDR | hsa-miR-145-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-15014 |
| MNDR | hsa-miR-145-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-15015 |
| MNDR | hsa-miR-145-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-15016 |
| MNDR | hsa-miR-145-5p | Pituitary acth hypersecretion | MNDR-E-MI-15017 |
| MNDR | hsa-miR-145-5p | Stroke lacunar | MNDR-E-MI-15018 |
| MNDR | hsa-miR-145-5p | Barrett's carcinogenesis | MNDR-E-MI-15019 |
| MNDR | hsa-miR-145-5p | Breast cancer her3+ negative | MNDR-E-MI-15020 |
| MNDR | hsa-miR-145-5p | Duke B | MNDR-E-MI-15021 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCC1 | Homo sapiens | RR00023260 |
TOP